@article{TCR24188,
author = {Joe Mehanna and Fady GH. Haddad and Roland Eid and Matteo Lambertini and Hampig Raphaël Kourié},
title = {What is the role of HER2-specific antibody immunity in patients with HER2-positive early breast cancer receiving chemotherapy plus trastuzumab?},
journal = {Translational Cancer Research},
volume = {7},
number = {6},
year = {2018},
keywords = {},
abstract = {Breast cancer is the most common malignancy among women worldwide and the leading cause of cancer death in many countries (1). In around 20% to 25% of breast cancer cases, there is an overexpression of HER2 or an amplification of its gene (HER2-positive subtype); HER2 is a transmembrane receptor implicated in tumor replication, invasion and dissemination (2). HER2-positive breast cancer is characterized by a worse prognosis, aggressive disease, higher mitotic index, worse nuclear grade and lymph nodes positivity (3).},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/24188}
}